20 Apr 2012 11:18

20 April 2012
EKF Diagnostics Holdings plc
("EKF" or the "Company")
Â
Publication of Annual Report and Notice of AGM
Â
EKF Diagnostics Holdings plc (AIM: EKF), a growing business within the in-vitro diagnostic devices market, announces that that the Annual Report and Accounts for the year ended 31 December 2011, the Notice of the Annual General Meeting and a Form of Proxy have been published today on the Company's website: www.ekfdiagnostics.com. These documents will be posted to shareholders shortly.
Â
The Company's Annual General Meeting will be held on Wednesday 23 May 2012 at 11am at the offices of Canaccord Genuity Limited, 88 Wood Street, London, EC2V 7QR.
Â
Â
Enquiries:
Â
EKF Diagnostics Holdings plc | Tel: 029 2071 0570 |
David Evans, Executive Chairman | Mob: 07740 084 452 |
Julian Baines, CEO | Mob: 07788 420 859 |
Canaccord Genuity Limited | Tel: 020 7523 8000 |
Jamie Adams / Mark Dickenson | |
Walbrook PRÂ Limited | Tel: 020 7933 8780 |
Paul McManus | Mob: 07980 541 893 or paul.mcmanus@walbrookpr.com |
Fiona Henson | Mob: 07886 335 992 or fiona.henson@walbrookpr.com |
Â
Â
About EKF Diagnostics Holdings plc
EKF Diagnostics Holdings plc was formed in July 2010 following the acquisition of EKF-diagnostic GmbH for €14.32m and refocused its strategy to one of building a substantial point of care diagnostics business. As part of this strategy, the Group has integrated three further acquisitions, Quotient Diagnostics Limited (acquired in October 2010 for a maximum of £5.41m), Argutus Medical Limited (acquired in December 2010 for £2.18m) and Stanbio Laboratory L.P. (acquired in June 2011 for a maximum of US$25.5m).
Â
The Company, with its head office in Cardiff and operations in London, Germany, Poland, Russia, Ireland and the US, is a leading diagnostics business, focused on the development, production and distribution of chemical reagents and analysers for the testing of Glucose, Lactate, Haemoglobin, Haematocrit and HbA1c.
Â
In May 2011 EKF entered into a distribution agreement with Alere Inc ("Alere"), a global diagnostics company, under which Alere was appointed the exclusive distributor of EKF's CLIA waived Hemo_Control device and cuvettes in the US, Canada and United Kingdom. The device is distributed in the US under the name HemoPoint H2.Â
Â
For more information please visit the website: www.ekfdiagnostics.co.uk
Â
Â
Â